ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019
Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- [The role of serological (rapid) tests for the early detection of HPV-related cancers].Dermatologie (Heidelberg, Germany) · 2026Pooled it
- Oropharyngeal cancer risk groups in the United States: a meta-analysis and SEER analysis.BMC cancer · 2025Pooled it
- Evidence-based guideline diagnosis, treatment, prevention and aftercare of oropharyngeal and hypopharyngeal carcinoma.German medical science : GMS e-journal · 2025Guideline
- Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis.Cancer · 2021Pooled it
- Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.Frontiers in immunology · 2021Pooled it
- Redefining oropharyngeal cancer in the HPV era: integrating precision medicine and immunotherapeutic frontiers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- In Vitro Model Characterizing Carcinogenic Progression of HPV-Positive Oropharyngeal Cancer.Cancers · 2026Article
- Diagnostic Performance of the PrevoCheck for the Detection of Human Papillomavirus 16-Driven Head and Neck Squamous Cell Carcinoma.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026Article
- Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection.Journal of the National Cancer Institute · 2026Article
- Beyond Women's Health: Long-Term Human Papillomavirus-Related Cancer Trends in Norway.The Journal of infectious diseases · 2025Observational
- Epidemiological Trends in the Characterization of Human Papillomavirus Virus-Related Oropharyngeal Cancer: A Global Perspective.Current oncology reports · 2025Review
- Article
- Advances in Prevention, Screening, and Early Detection of HPV-Associated Head and Neck Cancers.Viruses · 2025Review
- Direct Comparison of Alternative Blood-Based Approaches for Early Detection and Diagnosis of HPV-Associated Head and Neck Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Impact of screening for human papillomavirus-positive oropharyngeal cancers: a microsimulation-based modeling study.Journal of the National Cancer Institute · 2025Article
- Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study.Journal of the National Cancer Institute · 2025Article
- Human Papillomavirus Type 16 E6 Seroprevalence among Men Living with HIV without HPV-Driven Malignancies.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- [Epidemiology and prevention of oropharyngeal cancer : Summary of the new German S3 guideline].HNO · 2025Article
- Development of a multiplexed lateral flow assay for the serologic detection of HPV-associated head and neck cancer.Cancer biomarkers : section A of Disease markers · 2025Article
- The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer.Biomolecules · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Funding
Abstract
backgroundHuman papillomavirus type 16 (HPV16)-E6 antibodies are detectable in peripheral blood before diagnosis in the majority of HPV16-driven oropharyngeal squamous cell carcinoma (OPSCC), but the timing of seroconversion is unknown. PATIENTS AND
methodsWe formed the HPV Cancer Cohort Consortium which comprises nine population cohorts from Europe, North America and Australia. In total, 743 incident OPSCC cases and 5814 controls provided at least one pre-diagnostic blood sample, including 111 cases with multiple samples. Median time between first blood collection and OPSCC diagnosis was 11.4 years (IQR = 6-11 years, range = 0-40 years). Antibodies against HPV16-E6 were measured by multiplex serology (GST fusion protein based Luminex assay).
resultsHPV16-E6 seropositivity was present in 0.4% of controls (22/5814; 95% CI 0.2% to 0.6%) and 26.2% (195/743; 95% CI 23.1% to 29.6%) of OPSCC cases. HPV16-E6 seropositivity increased the odds of OPSCC 98.2-fold (95% CI 62.1-155.4) in whites and 17.2-fold (95% CI 1.7-170.5) in blacks. Seropositivity in cases was more frequent in recent calendar periods, ranging from 21.9% pre-1996 to 68.4% in 2005 onwards, in those with blood collection near diagnosis (lead time <5 years). HPV16-E6 seropositivity increased with lead time: 0.0%, 13.5%, 23.7%, and 38.9% with lead times of >30 years (N = 24), 20-30 years (N = 148), 10-20 years (N = 228), and <10 years (N = 301 cases) (p-trend < 0.001). Of the 47 HPV16-E6 seropositive cases with serially-collected blood samples, 17 cases seroconverted during follow-up, with timing ranging from 6 to 28 years before diagnosis. For the remaining 30 cases, robust seropositivity was observed up to 25 years before diagnosis.
conclusionsThe immune response to HPV16-driven tumorigenesis is most often detectable several decades before OPSCC diagnosis. HPV16-E6 seropositive individuals face increased risk of OPSCC over several decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.